PubMed Health⌕ Search

Biomedical subjects

Hideyuki Harada

Publications and source records attributed to Hideyuki Harada.

16 recordsLinked to original sources
PubMed2026

A multicenter randomized phase II/III trial of salvage treatment for refractory primary central nervous system lymphoma using tirabrutinib: JCOG2314 (ReSTART).

Primary central nervous system lymphoma (PCNSL) is an aggressive malignancy. Patients refractory to high-dose methotrexate-based induction therapy have an extremely poor prognosis. Although whole-brain radiotherapy (WBRT) is the standard salvage treatment and provides potent tumor control, early functional deterioration and late neurocognitive toxicity remain major concerns. A phase I/II trial on relapsed or refractory PCNSL demonstrated favorable efficacy and tolerability of tirabrutinib, a second-generation selective Bruton's tyrosine kinase inhibitor. Tirabrutinib's oral administration has enabled outpatient management. However, its clinical value for induction-refractory PCNSL remains uncertain. We designed a multicenter, randomized phase II/III trial (JCOG2314) to assess the non-inferiority of tirabrutinib to WBRT in overall survival and its potential to reduce functional deterioration and cognitive impairment. A total of 94 patients from 49 institutions will be enrolled over 4 years. The trial has been registered in the Japan Registry of Clinical Trials (study number: jRCT1031250645).

Humans↗
PubMed2026

Daily low-dose carboplatin or weekly carboplatin plus nab-paclitaxel for concurrent chemoradiotherapy in older patients with locally advanced non-small cell lung cancer (JCOG1914): A randomized phase 3 trial.

BACKGROUND: Daily low-dose carboplatin with concurrent thoracic radiotherapy is the standard treatment for older patients with unresectable locally advanced non-small cell lung cancer (LA-NSCLC) in Japan. METHODS: This open-label phase 3 trial was conducted at 38 institutions in Japan. Patients aged ≥ 75 years with LA-NSCLC were randomly assigned (1:1) to receive daily carboplatin (30 mg/m2) or weekly carboplatin (area under the curve, 2 mg·min/mL) plus nab-paclitaxel (30 mg/m2) with thoracic radiotherapy. Durvalumab maintenance therapy was recommended after treatment completion. The primary endpoint was overall survival, which was used to assess the non-inferiority of weekly carboplatin plus nab-paclitaxel compared to daily low-dose carboplatin. RESULTS: From December 2020 to March 2024, 124 patients were enrolled (carboplatin arm, 61 and carboplatin plus nab-paclitaxel arm, 63). In the planned interim analysis, the Bayesian predictive probability indicating the non-inferiority of carboplatin plus nab-paclitaxel compared with carboplatin in the final analysis was 8.0%, leading to early study termination for futility. The median overall survival was not estimable in the carboplatin arm; the estimated value in the carboplatin plus nab-paclitaxel arm was 26.1 months (hazard ratio, 1.56; 95% confidence interval, 0.79-3.11; p = 0.200). Two treatment-related and seven non-cancer-related deaths occurred in the carboplatin plus nab-paclitaxel arm. Patients in the carboplatin arm had better quality of life than those in the carboplatin plus nab-paclitaxel arm at 6 weeks (odds ratio, 0.39; 95% confidence interval, 0.18-0.81; p = 0.012). CONCLUSIONS: Daily low-dose carboplatin with concurrent thoracic radiotherapy remains the standard treatment for older patients with unresectable LA-NSCLC in Japan.

Humans↗
PubMed2006

Frequency and characteristics of docetaxel-induced radiation recall phenomenon.

PURPOSE: The aim of this study was to investigate the frequency and characteristics of a docetaxel-induced radiation recall phenomenon. METHODS AND MATERIALS: Past histories of radiotherapy and radiation recall phenomenon (RRP) were analyzed in 461 patients who were administered docetaxel at our hospital between September 2002 and November 2005. RESULTS: Of the 461 patients, 171 underwent radiotherapy before starting docetaxel. RRP was noted in 3 patients (1.8%). The 3 cases show that RRP tends to develop in patients treated with lower-energy photon beams of < or =6 MV and in patients with marked acute phase reactions during radiotherapy. CONCLUSIONS: The incidence of RRP induced by docetaxel was 1.8%, making it a comparatively rare condition. However, docetaxel is increasingly being used for patients with head and neck tumors, and caution regarding development of RRP is warranted after use of docetaxel after high-dose radiotherapy with photon beams of < or =6 MV.

Adult↗
PubMed2006

[Case series of localized nasal NK/T-cell lymphoma treated with preceding intensified local radiation therapy before systemic chemotherapy].

Nasal NK/T-cell lymphoma is EB virus-associated aggressive lymphoma, which is more prevalent in Asia. Previously, this lymphoma which was recognized as lethal midline granuloma, commonly presents with midline facial destructive lesions. In early stage I/II disease, radiation therapy exerts a powerful treatment outcome, however, toxic adverse events are indispensable and the tolerability of radiation therapy with chemotherapy has not been fully studied. It is imperative to offer an appropriate treatment for cure of this disease. We report consecutive 4 cases of nasal NK/T-cell lymphoma, which was treated with 56 Gy intensified local radiation therapy followed by systemic chemotherapy. Two cases complicated with grade 3 stomatitis during the treatment course and 3 cases were hospitalized due to the decrease of oral intake. The scheduled radiation chemotherapy was completed and resulted in complete response of disease in all cases. High intensified radiation therapy followed by chemotherapy may be effective for localized nasal NK/T-cell lymphoma.

Adolescent↗
PubMed2006

[Radiotherapy for bone metastases from hepatocellular carcinoma and pancreas cancer].

There are few reports on the treatment for bone metastases from hepatocellular carcinoma (HCC) and pancreas cancer. We evaluated the therapeutic effects of radiotherapy (RT) in patients with bone metastases from these cancers. Bone metastases from HCC are typically lytic and expansive. We evaluated 13 patients with 16 bone metastases from HCC undergoing RT (30-40 Gy, median 39 Gy) in our department from September 2002 to December 2004. Tumor regression was evaluated by CT or MRI. More than 50% tumor regression was achieved in 4 of 16 lesions (25%). Pain relief was achieved in 12/13 (92%). The median survival was 7 months (95% confidence interval [CI], 4-10 months), and the 6-month and 12-month local control rates were 81% and 67%, respectively. For patients with a limited life expectancy, standard dose RT is appropriate, however,with more than one year life expectancy, investigation employing dose escalation or combination with surgery or TAE is needed. Thirteen patients with 18 bone metastases from pancreas cancer received RT (20-30 Gy, median 30 Gy) from September 2002 to March 2005. The median survival was 3 months (95% CI, 1-6 months). Pain relief was achieved in 12/13 (92%). The prognosis of patients with bone metastases from pancreas cancer is still very poor, and a single fraction or short fraction schedule RT is appropriate.

Aged↗
PubMed2005

Evaluation of anatomy-based dwell position and inverse optimization in high-dose-rate brachytherapy of prostate cancer: a dosimetric comparison to a conventional cylindrical dwell position, geometric optimization, and dose-point optimization.

BACKGROUND AND PURPOSE: To compare treatment planning methods in high-dose-rate (HDR) brachytherapy of prostate cancer. In particular, to assess quantitatively the dosimetric superiority, if any, of the anatomy-based dwell position (ABDP) and inverse optimization (IO) over the conventional cylindrical dwell position (CDP), geometric optimization (GO), and dose-point optimization (DO) in terms of the determination of dwell positions and dwell times. PATIENTS AND METHODS: Between September 2002 and April 2003, 10 cases of treatment-planning CT images were taken for external radiotherapy for prostate cancer. Treatment planning computer software and the CT data were used to create hypothetical HDR brachytherapy applicator needles, which were properly implanted in the prostate. Six different plans including IO with ABDP (IO(ABDP)), IO with CDP (IO(CDP)), GO with ABDP (GO(ABDP)), GO with CDP (GO(CDP)), DO with ABDP (DO(ABDP)), and DO with CDP (DO(CDP)) were made for each case, that is, 60 plans in total. All plans were normalized so that the D(95) should be equal to 100% of the prescribed dose. Dose-volume histograms from all 60 plans were analyzed, and multiple implant quality indices, including CI, EI, DNR, %V(R 75), %V(B 75), and %V(U 150) for each plan, were extracted and compared. Then, the best settings for IO(ABDP) regarding dwell position and dose limit were sought for. RESULTS: ABDP showed a statistically significantly lower EI (P<0.001), %V(R 75) (P=0.002), and %V(B 75) (P=0.015) than CDP. IO showed a statistically significantly lower %V(U 150) than GO (P=0.009), or than DO (P<0.001). Given a definition that a figure exceeding three-fold of the minimum figure of the index is clinically unacceptable, only in IO(ABDP) all index figures were clinically acceptable, while in the other five plans at least one index figure was unacceptable. CONCLUSIONS: In the CT-based treatment planning for prostate HDR brachytherapy, ABDP is useful to achieve a high conformity, which leads to a reduction of the doses to the bladder, rectum, and surrounding normal tissue. IO is useful to lower the urethral dose without sacrificing conformity. IO(ABDP) is recommended on the basis of the current study. However, this conclusion has been drawn from the idealized hypothetical settings, and some possibility remains that this conclusion is not always applicable to the real implants.

Brachytherapy↗
PubMed2005

[Initial clinical experience of proton therapy at Shizuoka Cancer Center].

PURPOSE: To present the initial experience and preliminary clinical results of patients treated mainly with proton irradiation at the newly developed proton therapy facility at Shizuoka Cancer Center. MATERIALS AND METHODS: We reviewed 125 patients who underwent proton therapy between July 2003 and December 2004. Of these 125 patients, 11 had head and neck malignancies, 15 non-small cell lung cancers, 22 hepatocellular carcinomas, 62 prostate cancers, and 15 other malignant tumors. RESULTS: Most patients experienced Grade 0-1 acute morbidities (NCI-CTC) in skin or mucosa, while a temporary Grade 2-3 reaction was observed in a high dose area. Response rates were 73% for H & N malignancies, 100% for NSCLC, and 77% for HCC. PSA evaluation for patients with prostate cancer revealed a high rate of complete response. CONCLUSION: The efficacy and safety of proton therapy at Shizuoka Cancer Center was demonstrated for patients with early-stage cancer or locally advanced disease.

Adolescent↗
PubMed2004

Concomitant mitral and tricuspid valve infective endocarditis: report of a case.

A rare case of native valve endocarditis affecting both the normal mitral and tricuspid valves is presented. A 25-year-old woman with an acute ischemic stroke was found to have vegetation secondary to infective endocarditis as the embolic source. One month after the onset of embolic cerebrovascular intervention, a valve repair with the implantation of artificial chordae, sliding commissuroplasty, and ring annuloplasty resulted in a complete recovery.

Adult↗
PubMed2003

[High-dose-rate interstitial brachytherapy using inverse planning for locally advanced cervical cancer].

A 56-year-old woman with bulky cervical cancer was treated with high-dose-rate interstitial brachytherapy combined with external beam irradiation and chemotherapy. Inverse planning (IP) was used in the treatment planning for brachytherapy. Source dwell positions were selected automatically, once the required information had been input, for example, to prohibit dwelling inside the organs at risk (OARs) and to permit dwelling inside the planning target volume with a 2-mm inner margin. IP was compared with conventional geometrical optimization (GO) and dose point optimization (DO). The dwell positions of 3 plannings (IP, GOIP, and DOIP) were the same as IP, while in the other 2 plannings (GOConv and DOConv) dwell positions had the same length in all the applicators without concern for anatomy. D90 was equalized in all plannings as 100% prescription dose, and so the coverage index was always 90%. There was no definite tendency in dose non-uniformity ratio in the 5 plannings. As for sparing OARs such as the bladder, urethra, and rectum, IP showed the best % V75. The calculation time of the computer was fast enough. This is the first report in Japan on the clinical use of IP in interstitial brachytherapy, and it implies the usefulness of IP.

Brachytherapy↗
PubMed2003

Batista operation with aortic valve replacement for valvular cardiomyopathy.

We performed a successful Batista operation with aortic valve replacement (AVR), graft replacement of the ascending aorta, and tricuspid annuloplasty for a patient with valvular cardiomyopathy with severe aortic stenosis, an ascending aortic aneurysm, and grade 3 tricuspid regurgitation.

Aortic Aneurysm, Thoracic↗
PubMed2003

Large bronchial cyst causing compression of the left atrium.

We describe here a case with a large bronchogenic cyst treated by surgical resection, who presented with evidence of left atrial overload on electrocardiogram (ECG). The 50-year-old male patient presented with the chief complaint of heaviness in the chest on exertion. An ECG revealed evidence of left atrial overload, and echocardiography and imaging revealed a mass having a maximum diameter of 9 cm on the cranial aspect of the left atrium, caudal to the tracheal bifurcation. The patient was treated by surgical resection of the cystic mass via right anterolateral thoracotomy. His postoperative course was satisfactory and the patient was relieved of his main symptom.

Bronchogenic Cyst↗
PubMed2002

Replacement of a thrombosed valve after the Bentall procedure.

A 50-year-old man developed thrombosis in the valve of a Björk-Shiley prosthesis that had been used for composite graft replacement of the aortic valve and ascending aorta 8 years previously. The thrombosed valve was removed, and because of the narrow aortic valve ring, it was replaced using patch enlargement of the aortic annulus without replacement of the conduit.

Blood Vessel Prosthesis Implantation↗
PubMed2002

Composite graft replacement after aortic valvuloplasty in Takayasu arteritis.

A 24-year-old woman had undergone valvuloplasty of the aortic valve and external reinforcement of an aneurysm of the ascending aorta during the active phase of Takayasu arteritis 1 year prior to admission to our hospital. On examination, she was diagnosed as having a large false aneurysm of the ascending aorta with annuloaortic ectasia and severe aortic regurgitation, bilateral common carotid artery aneurysms with a left internal carotid artery saccular aneurysm, and bilateral subclavian artery and right vertebral artery obstructions due to Takayasu arteritis. Because of the risk of rupture, surgical intervention was carried out in spite of the fact that aortitis was in the active phase.

Adult↗
PubMed2002

Traumatic coronary artery dissection.

A 14-year-old boy sustained blunt chest trauma resulting in dissection of the left main coronary artery, postinfarction left ventricular aneurysm, mitral regurgitation, and tricuspid regurgitation. He underwent pericardial patch angioplasty of the left main coronary artery, left ventricular aneurysmectomy, mitral valvuloplasty, and tricuspid annuloplasty. The patient continues to do well 4 years after operation.

Accidents, Traffic↗